Krystal Biotech, Inc. (KRYS) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-02-17

Business type: Asset play

How it makes money

It earns $389.1 million in annual revenue from VYJUVEK, a topical gene therapy for DEB that achieved a 94% gross margin in 2025.

Profit is driven by the commercialization of VYJUVEK, a first-of-its-kind redosable gene therapy for dystrophic epidermolysis bullosa (DEB). Unlike traditional one-time gene therapies, this product is applied topically to wounds, requiring repeat administration to maintain the delivery of functional COL7A1 genes.

Revenue growth depends on successful pricing negotiations with government authorities in Europe and Japan. While the company sells directly in major markets, it utilizes a specialty distributor network to reach other international territories.

What could damage it

Earnings could be permanently impaired if pricing negotiations in France, expected to continue until 2027, fail to reach sustainable reimbursement levels.

The company's financial health is currently dependent on the commercial success of a single product. Because it is launching in highly regulated European markets, failure to secure favorable pricing from reimbursement authorities in Germany, France, or Italy would restrict its primary revenue stream.

Additionally, as its products are regulated as biologics, they may eventually face competition from biosimilars approved through abbreviated regulatory pathways, which could erode its pricing power.

About Krystal Biotech, Inc.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Other companies in Biotechnology